Jane Street Group, LLC Affimed N.V. Call Options Transaction History

Jane Street Group, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	SELL	$3.69 - $5.65 $362,358 - $554,830	-98,200 Reduced 66.58%	49,300 $215,000
Q4 2021 Feb 15, 2022	SELL	$5.37 - $7.07 $23,628 - $31,108	-4,400 Reduced 2.9%	147,500 $814,000
Q3 2021 Nov 16, 2021	BUY	$5.54 - $7.51 $650,950 - $882,425	117,500 Added 341.57%	151,900 $939,000
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $166,492 - $243,960	21,400 Added 164.62%	34,400 $292,000
Q4 2020 Feb 17, 2021	BUY	$3.16 - $7.03 $41,080 - $91,390	13,000 New	13,000 $76,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.